Halozyme Therapeutics earnings were $485.4M for the trailing 12 months ending Mar 31, 2025, with 57.1% growth year over year. The latest HALO earnings report on Mar 31, 2025 announced Q1 2025 earnings of $118.1M, down 13.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, HALO reported annual earnings of $444.1M, with 57.7% growth.
HALO past earnings growth
How has HALO's earnings growth performed historically?
Halozyme Therapeutics Earnings Reports & History FAQ
What were Halozyme Therapeutics's earnings last quarter?
On HALO's earnings call on Invalid Date, Halozyme Therapeutics (NASDAQ: HALO) reported Q1 2025 earnings per share (EPS) of $0.96, up 57.38% year over year. Total HALO earnings for the quarter were $118.10 million. In the same quarter last year, Halozyme Therapeutics's earnings per share (EPS) was $0.61.
Is Halozyme Therapeutics profitable or losing money?
As of the last Halozyme Therapeutics earnings report, Halozyme Therapeutics is currently profitable. Halozyme Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $485.36 million, a 52.25% increase year over year.
What was HALO's earnings growth in the past year?
As of Halozyme Therapeutics's earnings date in Invalid Date, Halozyme Therapeutics's earnings has grown 57.14% year over year. This is 45.29 percentage points higher than the US Biotechnology industry earnings growth rate of 11.85%. HALO earnings in the past year totalled $485.36 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.